NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (AMEX: PRW), a developer of first-in-class, carbohydrate-based targeted therapeutic compounds to treat cancer and liver fibrosis, has issued an open letter to shareholders from Theodore D. Zucconi, Ph.D., President of the Company. The Company’s Annual Shareholders Meeting is being held today. For more information, please visit our website: www.pro-pharmaceuticals.com.
